Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 9, 2009, Pages 1336-1341

  Franssen, Remco ^a   Sankatsing, Raaj R ^a   Hassink, Elly ^e   Hutten, Barbara ^a   Ackermans, Mariette T ^b   Brinkman, Kees ^f   Oesterholt, René ^b   Arenas Pinto, Alejandro ^g   Storfer, Stephen P ^h   Kastelein, John J ^a   Sauerwein, Hans P ^c   Reiss, Peter ^d   Stroes, Erik S ^a  

^a Department of Vascular Medicine ^*

^b Department of Clinical Chemistry

^c Tropical Medicine   (Brazil)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e IATEC BV   (Netherlands)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Apolipoprotein A I; High density lipoprotein cholesterol; Metabolism; Nevirapine; Stable isotopes

Indexed keywords

ABACAVIR; APOLIPOPROTEIN A1; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOA1 PROTEIN, HUMAN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PRIORITY JOURNAL; VIRUS LOAD; BLOOD; CLINICAL TRIAL; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; KINETICS; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TREATMENT OUTCOME; UNITED KINGDOM; UPREGULATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LONDON; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NETHERLANDS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; UP-REGULATION; VIRAL LOAD;

EID: 69849103941     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.192088     Document Type: Article

References (34)

1. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883. (Pubitemid 28279721)
2. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De WS, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
3. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15: 2407-2414.
4. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
5. Phillips A, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, Williams I, Drummond F, Duprez D, Lundgren J. and others for the SMART Study Group. Interruption of ART and Risk of Cardiovascular Disease: Findings from SMART. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles. 25-32 2007.
6. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005; 46:1792-1798.
7. Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-1389.
8. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4:29-36.
9. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005; 19:917-925.
10. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen I, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263.
11. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122.
12. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
13. Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic importance. Chem Rev. 2004;104:119-137.
14. Geukers VG, Oudshoorn JH, Taminiau JA, van der Ent CK, Schilte P, Ruiter AF, Ackermans MT, Endert E, Jonkers-Schuitema CF, Heymans HS, Sauerwein HP. Short-term protein intake and stimulation of protein synthesis in stunted children with cystic fibrosis. Am J Clin Nutr. 2005; 81:605-610.
15. Frenais R, Ouguerram K, Maugeais C, Marchini JS, Benlian P, Bard JM, Magot T, Krempf M. Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res. 1999; 40:1506-1511.
16. Velez-Carrasco W, Lichtenstein AH, Barrett PH, Sun Z, Dolnikowski GG, Welty FK, Schaefer EJ. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins. J Lipid Res. 1999;40:1695-1700.
17. Velez-Carrasco W, Lichtenstein AH, Li Z, Dolnikowski GG, Lamon-Fava S, Welty FK, Schaefer EJ. Apolipoprotein A-I and A-II kinetic parameters as assessed by endogenous labeling with [(2)H(3)]leucine in middle-aged and elderly men and women. Arte-rioscler Thromb Vasc Biol. 2000;20:801-806.
18. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest. 1990;85: 804-811.
19. Chetiveaux M, Ouguerram K, Zair Y, Maugere P, Falconi I, Nazih H, Krempf M. New model for kinetic studies of HDL metabolism in humans. Eur J Clin Invest. 2004;34:262-267.
20. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ. Interrelationships between human apolipoprotein A-I and apoli-poproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol. 2004;24:1703-1707.
21. Ooi EM, Watts GF, Farvid MS, Chan DC, Allen MC, Zilko SR, Barrett PH. High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. Eur J Clin Invest. 2006;36: 626-632.
22. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab. 2006;91:973-979.
23. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cho-lesteryl ester transfer protein deficiency. J Clin Invest. 1993;92: 1650-1658.
24. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Bjorkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057-1064.
25. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-anal-ysis of randomized controlled trials. J Am Coll Cardiol. 2005;45: 185-197.
26. Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol. 2006;17:431-439.
27. Tohyama J, Billheimer JT, Fuki IV, Rothblat GH, Rader DJ, Millar JS. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis. 2009;204:418-423.
28. van der Valk M. Rise in HDL cholesterol associated with nevirapine containing antiretroviral therapy in HIV-1 infected patients is sustained over 48 weeks of treatment. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection. 29-110-2001. Abstract.
29. Sankatsing RR, Wit FW, Vogel M, de GE, Brinkman K, Rockstroh JK, Kastelein JJ, Stroes ES, Reiss P. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis. 2009;202: 589-595.
30. Van Lenten BJ, Reddy ST, Navab M, Fogelman AM. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol. 2006;26:1687-1688.
31. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
32. Kono M, Okumura Y, Tanaka M, Nguyen D, Dhanasekaran P, Lund-Katz S, Phillips MC, Saito H. Conformational flexibility of the N-terminal domain of apolipoprotein a-I bound to spherical lipid particles. Biochemistry. 2008;47:11340-11347.
33. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest. 1973;52:32-38.
34. Mukhamedova N, Rose H, Cui HL, Grant A, Tchoua U, Dart A, Bukrinsky M, Sviridov D. Antiretroviral compounds and cholesterol efflux from macrophages. Atherosclerosis. In press.